According to a late-night filing, Apogee Therapeutics Inc. filed for an IPO. The biotech firm did not specify the number of shares or price range it intended to sell. Jefferies, TD Cowen and other underwriters are involved in the deal. The company will trade on Nasdaq with the symbol APGE. Waltham-based company seeks to develop treatments for “highly unmet needs” such as atopic skin dermatitis and chronic obstructive lung disease. The company’s losses were $12.5 million or $2.51 per share in the quarter ended March 31 compared with $4.3 million or $4.19 per share in the previous period. The prospectus stated that “even if the offering is successful, substantial additional capital will be required to finance our future operations.”